Hh pathway inhibitors and clinical trials in hematologic malignancies
| Name . | Action . | Producer . | Active hematologic clinical trial . | Trial number* . |
|---|---|---|---|---|
| Cyclopamine | SMO antagonist | Generic | Nonclinical | NA |
| LDE225 | SMO antagonist | Novartis | Phase 1: CML, in combination with nilotinib | NCT1456676 |
| LEQ506 | SMO antagonist | Novartis | Solid tumors only (phase 1 and 2) | NA |
| GDC-0449 | SMO antagonist | Genentech | Phase 1b: myeloma in first remission or first relapse after ASCT | NCT01330173 |
| BMS-833923 | SMO antagonist | BMS | Phase 1: CML, in combination with dasatinib | NCT 01218477 |
| Phase 1b: myeloma, in combination with lenalidomide with dexamethasone or bortezomib with dexamethasone | NCT00884546 | |||
| IPI926 | SMO antagonist | Infinity | Phase 2: myelofibrosis | NCT01371617 |
| PF-04449913 | SMO antagonist | Pfizer | Phase 1: myeloid malignancies, including CML, in combination with dasatinib or bosutinib | NCT00953758 |
| GANT61 | Direct GLI inhibition | Generic | Nonclinical | NA |
| Name . | Action . | Producer . | Active hematologic clinical trial . | Trial number* . |
|---|---|---|---|---|
| Cyclopamine | SMO antagonist | Generic | Nonclinical | NA |
| LDE225 | SMO antagonist | Novartis | Phase 1: CML, in combination with nilotinib | NCT1456676 |
| LEQ506 | SMO antagonist | Novartis | Solid tumors only (phase 1 and 2) | NA |
| GDC-0449 | SMO antagonist | Genentech | Phase 1b: myeloma in first remission or first relapse after ASCT | NCT01330173 |
| BMS-833923 | SMO antagonist | BMS | Phase 1: CML, in combination with dasatinib | NCT 01218477 |
| Phase 1b: myeloma, in combination with lenalidomide with dexamethasone or bortezomib with dexamethasone | NCT00884546 | |||
| IPI926 | SMO antagonist | Infinity | Phase 2: myelofibrosis | NCT01371617 |
| PF-04449913 | SMO antagonist | Pfizer | Phase 1: myeloid malignancies, including CML, in combination with dasatinib or bosutinib | NCT00953758 |
| GANT61 | Direct GLI inhibition | Generic | Nonclinical | NA |
NA indicates not applicable.